Gary Pigeau received his Ph.D. in Biotechnology from Brock University in St. Catharines, Ontario. He completed a postdoctoral fellowship at the University of Alberta with a visiting scientist appointment at the University of Oxford. Gary moved to private industry in 2008, where his research group focused on process development and scale-up of a proprietary bioprocess technology. He then moved to commercial, large-scale biomanufacturing in 2013. Gary joined Cytiva, formerly part of GE Healthcare’s Life Sciences business, and the Centre for Advanced Therapeutic Cell Technologies (CATCT) at CCRM in 2016. He serves as Director of the collaborative facility in Toronto, Ontario with focus on biology support for New Product Introductions, internal technology development projects and contract process development services in cell and gene therapy.
- Texas Heart Institute studying how stem cells treat heart failure
- CRISPR-Cas enzyme-based diagnostics to detect SARS-CoV-2 infection
- New Poll Demonstrates Bipartisan Support for Therapies that Target Aging and Associated Research
- Experimental mRNA HIV Vaccine Safe, Shows Promise in Animals
- Using fungal vaccine to train stem cells and enhance immune response to infections
- ‘Blastoids’ made of stem cells offer a new way to study fertility
- Reimagining stem cell cultivation
- Stem Cells or PRP for Equine Tendon and Ligament Injuries?
- First-ever pig-to-human heart transplant offers hope for thousands in need of organs
- Bayer Strikes “Mammoth” CRISPR Deal to Bolster Cell and Gene Therapy
- Pfizer Makes Foray Into CRISPR, Inking $1.35 Billion Deal With Beam Therapeutics
- For everything there is a season
- Stem Cell Therapy Safe, Shows Potential to Slow Progression in Trial
- Type 1 Diabetes Trial Tests Insulin-Secreting Implants Derived from Stem Cells
- New potential drugs for muscle dystrophy found using stem cells